Commercially Available Cannabis Products for Immune Support

Last updated: February 28, 2024
Sponsor: Center For Interventional Pain and Spine
Overall Status: Active - Recruiting

Phase

N/A

Condition

Acute Rhinitis

Common Cold

Covid-19

Treatment

Immune Support Supplement

Clinical Study ID

NCT05944705
CannabisforImmuneSupport
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 18 years of age or older
  2. Able to read and write in English
  3. Active participants in the Pennsylvania medical marijuana program (for cannabisproduct users)
  4. Currently experiencing one or more of the following symptoms due to an acute illness:
  5. Fever or chills
  6. Cough
  7. Fatigue
  8. Muscle or body aches
  9. Headache
  10. Sore throat
  11. Congestion or runny nose
  12. Nausea or Vomiting
  13. Diarrhea
  14. Agrees to consume their chosen hemp or cannabis product (for the cannabis arm) and tonot use a different hemp or cannabis product through the duration of the study
  15. Agrees to continue to abstain from using hemp or cannabis (for the non-cannabis/hempusing arm)
  16. Must have smart phone or email and access to the internet
  17. Be able to comply with study requirements including baseline, completion of electronicquestionnaires, and study timeline parameters.

Exclusion

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant.
  2. Known allergy to any compounds in hemp or cannabis.
  3. Endorses suicidal intent
  4. Immunocompromised individuals
  5. Unwilling or unable to comply with study procedures
  6. Terminal Illness with life expectancy less than 1 year

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Immune Support Supplement
Phase:
Study Start date:
November 01, 2023
Estimated Completion Date:
December 01, 2024

Study Description

In the era of COVID-19, there has been much speculation about the risks and benefits of cannabis use for immune support. It is well known that the endocannabinoid system plays a role in the regulation of the immune response and its role in inflammation reduction may be useful in terms of a potential adjunctive therapy for acute infection. Cannabis products vary widely in their composition and may have a varying effect based on the strain and the associated terpenes. Here, we aim to track cannabis and hemp usage during an acute infection to understand it's safety and effects in a symptomatic population.

Given the fast and widespread acceptance and use of cannabis products in the US market, commercial use has outpaced randomized controlled trials (RCTs). Thus, carefully designed observational studies are important to understand how these products are affecting consumers. Prospective observational designs allow for real-world examinations of commercialized products with similar effect sizes to RCTs. Although observational designs have some drawbacks, a review covering 1,583 meta-analyses across 228 medical conditions compared the effect sizes from RCTs with those from observational studies for the same medical conditions and found no differences between the two. (1) These data provide evidence that a carefully designed observational study can help us better understand the effects of commonly used products such as cannabis edibles. The aim of this observational study is to evaluate the safety and associated effects of commercially available cannabis products in the US in symptomatic individuals seeking them for immune support.

Connect with a study center

  • Center for Interventional Pain and Spine

    Bryn Mawr, Pennsylvania 19010
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.